Probiotic-Muscle Study
Primary Purpose
Old Age; Debility, Muscle Weakness, Protein Deregulation
Status
Completed
Phase
Not Applicable
Locations
Ireland
Study Type
Interventional
Intervention
Probiotic
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Old Age; Debility
Eligibility Criteria
Inclusion Criteria:
- Age: ≥65 y
- Sex: males and female
- Body mass index (BMI) between 20-35 kg/m2
- Non-smokers
- Generally healthy according to responses to a standard health screening questionnaire
Exclusion Criteria:
- Cancer (malignancy in the past 5 years)
- CVD
- Chronic kidney disease
- Liver failure
- Diabetes or pre-diabetes
- Conditions that will affect the ability to consume, digest and/or absorb the study supplement (i.e. gastrointestinal disease)
- Smokers
- Excess alcohol intake
- Regular resistance training
- Total walking incapacity
- Musculoskeletal or neuromuscular impairments
- Medications interfering with muscle metabolism
- Ongoing probiotic supplementation
- Antibiotic use in the previous 6 weeks
- Significant body mass loss in the 1 month period prior to the study
Sites / Locations
- University College Dublin
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Placebo
Probiotic
Arm Description
Maltodextrin containing capsule
Probiotic containing capsule
Outcomes
Primary Outcome Measures
Myofibrillar protein synthesis
Measured as fractional synthetic rate (%/day) over a 2-d period after each supplementation arm and in response to a plant-based diet
Pattern of change in plasma total amino acid, essential amino acid and leucine concentrations
Assessed via GC-MS.
Secondary Outcome Measures
Changes in microbiome composition
Assessed in faecal samples via 16s rRNA analysis
Change in metabolome
Assesed in blood and faecal water via 600 MHz nuclear magnetic resonance (NMR) spectrometry
Changes in gut hormones
ELISA (enzyme-linked immunosorbent assay)
Changes in gut/digestion-related complaints
Assessed via the Gastrointestinal Symptom Rating Scale (GSRS), where minimum and maximum values are: no discomfort at all, and very severe discomfort respectively (higher score means worse outcome).
Changes in bowel movement
Assessed via the Bristol Stool chart, where average faecal appearance is indicated out of seven options available
Changes in strength
Assessed via handgrip strength using a handgrip dynamometer
Changes in immuno-surveillance
Assessed via the Common Cold Questonnaire (CCQ), where minimum and maximum values are: none, and severe respectively (higher score means worse outcome).
Changes in appetite
Assessed via the Visual Analogue Scale (VAS) during 3 days of the trial period and after the protein-containing beverage, where the left and right side of the scale indicate: not hungry at all, and extremely hungry respectively (there is not an assigned better or worse outcome for this scale)
Full Information
NCT ID
NCT04297111
First Posted
March 3, 2020
Last Updated
November 2, 2022
Sponsor
University College Dublin
Collaborators
Kerry Group
1. Study Identification
Unique Protocol Identification Number
NCT04297111
Brief Title
Probiotic-Muscle Study
Official Title
Effect of Bacillus Coagulans on Skeletal Muscle Protein Synthesis in Response to Vegetable Protein Ingestion
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
November 25, 2019 (Actual)
Primary Completion Date
October 3, 2020 (Actual)
Study Completion Date
December 1, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University College Dublin
Collaborators
Kerry Group
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study will examine the effect of probiotic supplementation (Bacillus coagulans) on muscle protein synthesis in older adults in response to a plant-based diet.
The investigators hypothesize that probiotic supplementation will enhance the digestibility of plant protein, therefore increasing the proportion of ingested amino acids that appear in systemic circulation and enhancing rates of muscle protein synthesis.
Detailed Description
There is increasing interest in the use of plant-based proteins, both from the perspectives of global sustainability and growing consumer markets; however, plant-based proteins are known to have lower digestibility and lower ability to stimulate muscle protein synthesis (an important determinant of muscle mass) compared with animal-based proteins. Emerging evidence indicates that the probiotic Bacillus coagulans GBI-30, 6086 (GanedenBC30) can enhance plant protein digestibility. As such, Bacillus coagulans treatment may augment rates of muscle protein synthesis in response to plant-based protein intake in humans, by increasing the proportion of ingested amino acids that appear in systemic circulation after a plant meal, as circulating amino acids act as both a trigger to stimulate muscle protein synthesis in humans as well as providing the building block for new muscle tissue. An increase in muscle protein synthesis rates would be particularly critical in older adults as it is well established that one of the key mechanisms driving the loss of muscle mass with age is a reduction in muscle protein synthesis rates in response to dietary protein intake. Therefore, if probiotic supplementation can improve muscle protein synthesis rates following plant protein consumption, this indicates it may represent an effective and environmentally sensitive strategy to attenuate adverse age-related loss of muscle mass and muscle function. This is critical as the maintenance of skeletal muscle health is an important factor in the preservation of independence and quality of life as we age.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Old Age; Debility, Muscle Weakness, Protein Deregulation, Protein Deposition
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
The study will be a randomised, double-blind, placebo-controlled crossover study. Each participant will undergo 8 weeks of Bacillus coagulans (probiotic) supplementation and 8 weeks of placebo supplementation in a counterbalanced order. There will be a 5-day trial period at the end of each supplementation phase. There will be a wash-out period of 8 weeks between probiotic and placebo supplementation.
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Maltodextrin containing capsule
Arm Title
Probiotic
Arm Type
Experimental
Arm Description
Probiotic containing capsule
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotic
Intervention Description
GanedenBC30 (Bacillus coagulans GBI-30, 6086) capsule made of 1 billion colony forming units (cfu). Description: pure cell mass of an L-(+) lactic acid-producing, gram-positive, spore-forming shaped bacterium that is aerobic to microaerophilic. Maltodextrin used as filler.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Maltodextrin capsule, no active ingredient
Primary Outcome Measure Information:
Title
Myofibrillar protein synthesis
Description
Measured as fractional synthetic rate (%/day) over a 2-d period after each supplementation arm and in response to a plant-based diet
Time Frame
6 months
Title
Pattern of change in plasma total amino acid, essential amino acid and leucine concentrations
Description
Assessed via GC-MS.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Changes in microbiome composition
Description
Assessed in faecal samples via 16s rRNA analysis
Time Frame
6 months
Title
Change in metabolome
Description
Assesed in blood and faecal water via 600 MHz nuclear magnetic resonance (NMR) spectrometry
Time Frame
6 months
Title
Changes in gut hormones
Description
ELISA (enzyme-linked immunosorbent assay)
Time Frame
6 months
Title
Changes in gut/digestion-related complaints
Description
Assessed via the Gastrointestinal Symptom Rating Scale (GSRS), where minimum and maximum values are: no discomfort at all, and very severe discomfort respectively (higher score means worse outcome).
Time Frame
6 months
Title
Changes in bowel movement
Description
Assessed via the Bristol Stool chart, where average faecal appearance is indicated out of seven options available
Time Frame
6 months
Title
Changes in strength
Description
Assessed via handgrip strength using a handgrip dynamometer
Time Frame
6 months
Title
Changes in immuno-surveillance
Description
Assessed via the Common Cold Questonnaire (CCQ), where minimum and maximum values are: none, and severe respectively (higher score means worse outcome).
Time Frame
6 months
Title
Changes in appetite
Description
Assessed via the Visual Analogue Scale (VAS) during 3 days of the trial period and after the protein-containing beverage, where the left and right side of the scale indicate: not hungry at all, and extremely hungry respectively (there is not an assigned better or worse outcome for this scale)
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age: ≥65 y
Sex: males and female
Body mass index (BMI) between 20-35 kg/m2
Non-smokers
Generally healthy according to responses to a standard health screening questionnaire
Exclusion Criteria:
Cancer (malignancy in the past 5 years)
CVD
Chronic kidney disease
Liver failure
Diabetes or pre-diabetes
Conditions that will affect the ability to consume, digest and/or absorb the study supplement (i.e. gastrointestinal disease)
Smokers
Excess alcohol intake
Regular resistance training
Total walking incapacity
Musculoskeletal or neuromuscular impairments
Medications interfering with muscle metabolism
Ongoing probiotic supplementation
Antibiotic use in the previous 6 weeks
Significant body mass loss in the 1 month period prior to the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Helen Roche, PhD
Organizational Affiliation
University College Dublin
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Caoielann Murphy, PhD
Organizational Affiliation
University College Dublin
Official's Role
Study Director
Facility Information:
Facility Name
University College Dublin
City
Dublin
Country
Ireland
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Research results will be published in a peer-reviewed journal once the study has finalised and the data has been analized.
Learn more about this trial
Probiotic-Muscle Study
We'll reach out to this number within 24 hrs